Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does for the Foster City, Calif.-based biotech’s pipeline. The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which focused on China and the Trump administration’s most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA’s about-face on the recent vaccine application from Moderna. View full story: 00:00 - Introduction 02:34 - Gilead's Arcellx Buy 11:14 - ctDNA Surrogate Endpoints 21:59 - PhRMA Forum Takeaways 29:19 - FDA Moderna U-turn To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

You can listen to Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint online on Radio and Podcast. Open the player on this page to stream the available audio.

Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint is an episode from BioCentury This Week by BioCentury.

This episode is 35:25 long.

This episode was published on Feb 24, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioCentury This Week when more episodes are available from the podcast feed.